CCTL019B2003I: Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) in diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release

Title
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) in diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
Principal Investigator
Veltri, Lauren
Phase
NA
Age Group
Adult
Applicable Disease Sites
Leukemia
Lymphoma
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Crystal Peck, RN
BMT Coordinator
Phone: +1 304-598-4500
Email:

View on ClinicalTrials.gov